Register
Login:
Share:
Email Facebook Twitter

Fund Manager Chris Bailey talks about an opportunist 2017 for investors Watch here

Fund Manager Chris Bailey talks about an opportunist 2017 for investors


Physiomics Share Chat (PYC)



Share Price: 1.75Bid: 1.70Ask: 1.80Change: 0.00 (0.00%)No Movement on Physiomics
Spread: 0.10Spread as %: 5.88%Open: 1.775High: 1.775Low: 1.75Yesterday’s Close: 1.75


Share Discussion for Physiomics


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


DRAEY
Posts: 1,427
Off Topic
Opinion:No Opinion
Price:1.775
Re-Val Rns
Fri 14:21
None of them goes bust the tow company has been trading over 10 years and been carried on like that. Val 201 definitely will get the deal by the end of the year. Gla
 
preemo
Posts: 141
Off Topic
Opinion:No Opinion
Price:1.775
RE: Val Rns
Fri 13:09
Depends which one goes bust first!
DRAEY
Posts: 1,427
Off Topic
Opinion:No Opinion
Price:2.075
Val Rns
Wed 09:30
Good Rns in valirx about Val 201. Pyc has a good stake in Val and royality payment . This can go on every year with royalty payment. Gla
earlsfield
Posts: 3,502
Off Topic
Opinion:No Opinion
Price:2.05
RNS
Wed 07:53
The only interesting thing about the update is hat it seems to confirm future payments from SAR, by talking about an initial payment from them. The rest is fairly benign
earlsfield
Posts: 3,502
Off Topic
Opinion:No Opinion
Price:2.075
RE: Re- do we get a cut
10 Jan '17
Yes agreed. Re read the notes in the FY13 accounts. Looks clear to me. Payments due in which could be v material to this company
Ralphiebabe
Posts: 1,048
Off Topic
Opinion:No Opinion
Price:2.075
Re- do we get a cut
10 Jan '17
Refer to my posts with Draey and Earlsfield last week.
Personally, from reading RNS with SAR and VAL with PYC concerning their Compound Modelling, I think PYC will receive a payment ( a small %) everytime SAR and VAL receive payment including licensing deals.

If I'm right, PYC should announce a RNS about this within the next 2 months.
desamax
Posts: 904
Off Topic
Opinion:No Opinion
Price:2.075
do we get a cut
9 Jan '17
Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce the attainment of a US$2.0 million success milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, Inc. (NASDAQ: SRRA), formerly, until today, ProNAi Therapeutics, Inc.
earlsfield
Posts: 3,502
Off Topic
Opinion:No Opinion
Price:2.05
SAR RNS
9 Jan '17
out......
earlsfield
Posts: 3,502
Off Topic
Opinion:No Opinion
Price:2.175
RE: sp
6 Jan '17
Decent RNS. Just the start. Expecting much more newsflow to come
Fazzx
Posts: 285
Off Topic
Opinion:No Opinion
Price:2.00
sp
6 Jan '17
expecting a good rise today...

Tough to normally get grants without a good business plan..




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.